Voriconazole Compared With Itraconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Randomized Trial Of Safety And Tolerability Of Intravenous/Oral Voriconazole Versus Intravenous/Oral Itraconazole For Long-Term Antifungal Prophylaxis In Allogeneic Hematopoietic Stem Cell Transplant Recipients
Sponsor: Jonsson Comprehensive Cancer Center
A NA clinical study on Cancer, this trial is completed. The trial is conducted by Jonsson Comprehensive Cancer Center and has accumulated 7 data snapshots since 2003. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2021 — Jul 2024 [monthly]
Completed NA
-
Sep 2020 — Jan 2021 [monthly]
Completed NA
-
Jun 2018 — Sep 2020 [monthly]
Completed NA
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Completed NA
-
Jan 2017 — Feb 2017 [monthly]
Completed NA
First recorded
Nov 2003
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Jonsson Comprehensive Cancer Center
For direct contact, visit the study record on ClinicalTrials.gov .